Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmicals宣佈在早期阿爾茨海默氏病的Sabirnetug（ACU193）的ALTITUDE-AD 2期臨床試驗中爲首位患者服藥
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmicals宣佈在早期阿爾茨海默氏病的Sabirnetug（ACU193）的ALTITUDE-AD 2期臨床試驗中爲首位患者服藥
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。